HER-2與TMEM106B在腦膜瘤細(xì)胞增殖和血管生成過程中的表達(dá)及意義
發(fā)布時間：2019-04-27 10:38
【摘要】：目的:檢測腦膜瘤組織中的TMEM106B、HER-2、VEGF和CD34蛋白的表達(dá)情況,探討HER-2和TMEM106B蛋白與腦膜瘤細(xì)胞的增殖和血管生成的關(guān)系,以期進一步了解腦膜瘤的發(fā)生、進展的機制,可能為后續(xù)腦膜瘤的靶向治療提供實驗數(shù)據(jù)。方法:選取2007年1月1日-2015年12月31日南昌大學(xué)第一附屬醫(yī)院病理科腦膜瘤患者術(shù)后石蠟標(biāo)本50例,以及20例正常腦膜石蠟標(biāo)本作為對照,對照組腦膜組織均取自顱腦損傷后接受顱內(nèi)血腫清除術(shù)+去骨瓣減壓的患者。采用Max VisionTM免疫組化法分別檢測兩組樣本中TMEM106B、HER-2、VEGF和CD34蛋白的表達(dá)情況,并采用UTHSCSA Image Tool圖文分析軟件計算微血管密度(MVD)。結(jié)果:1.HER-2在本組腦膜瘤組織中有較高的陽性檢出率36%(18/50),但在正常腦膜組織中HER-2的表達(dá)均為陰性,兩者的表達(dá)差異具有統(tǒng)計學(xué)意義(X2=9.692,P0.05)。但對HER-2的進一步研究表明HER-2的陽性率并沒有隨著腦膜瘤組織的惡性程度的升高而升高,WHOI級腦膜瘤組織的HER-2陽性率為:28.6%(6/21),WHOII級腦膜瘤組織的HER-2陽性率為:44.4%(8/18),WHOIII級腦膜瘤組織的陽性率為:36.4%(4/11),其差異性沒有統(tǒng)計學(xué)意義(X2=2.007,P0.05)。2.TMEM106B在腦膜瘤組織中陽性檢出率82%(41/50),但在正常腦膜組織中TMEM106B的表達(dá)均為陰性,兩者表達(dá)差異有統(tǒng)計學(xué)意義(X2=39.586P0.05)。對TMEM106B的研究結(jié)果表明TMEM106B的陽性率未表現(xiàn)為隨著腦膜瘤組織的惡性程度的升高而升高情況,WHOI級腦膜瘤組織的TMEM106B陽性率為81%(17/21),WHOII級腦膜瘤組織的TMEM106B陽性率為77.8%(14/18),WHOIII級腦膜瘤組織的陽性率為90.9%(10/11),表達(dá)差異無統(tǒng)計學(xué)意義(X2=0.004,P0.05)。3.MVD和VEGF在正常腦膜瘤組織均為陰性,而在腦膜瘤組織中表達(dá)率顯著提高(18.04±19.85)和70%(35/50),差異均有統(tǒng)計學(xué)意義(X2=9.692,P0.05;T=9.427,P0.05),不同級別腦膜瘤中:WHOI級腦膜瘤組織的CD34和VEGF為:(5.77±10.18)和66.7%(14/21),WHOII、III級腦膜瘤組織中的CD34和VEGF陽性率為:(26.92±20.53)和72.41%(21/29),差異有統(tǒng)計學(xué)意義(P0.05)。4.經(jīng)Spearman秩相關(guān)分析,HER-2與VEGF、MVD均呈正相關(guān)。HER-2與VEGF呈正相關(guān)(r=0.113 P0.05),與MVD呈正相關(guān)(r=0.058,P0.05);TMEM106B與VEGF呈正相關(guān)(r=0.293 P0.05)、與MVD呈正相關(guān)(r=0.146P0.05);VEGF與MVD呈正相關(guān)(P0.05,r=0.170)。HER-2與TMEM106B呈正相關(guān)(P0.05,r=0.115)。結(jié)論:1.HER-2和TMEM106B在腦膜瘤細(xì)胞中均存在過表達(dá),但其陽性表達(dá)率與腦膜瘤的惡性程度無統(tǒng)計學(xué)意義,HER-2和TMEM106B均參與了腦膜瘤細(xì)胞的增殖和血管的生成。2.HER-2可能通過調(diào)節(jié)TMEM106B來影響腦膜細(xì)胞的增殖和血管生成。
[Abstract]:Objective: to detect the expression of TMEM106B,HER-2,VEGF and CD34 proteins in meningiomas and to explore the relationship between HER-2 and TMEM106B proteins and the proliferation and angiogenesis of meningioma cells, so as to further understand the pathogenesis and progression of meningiomas, and to explore the relationship between the expression of HER-2 and TMEM106B proteins and the proliferation and angiogenesis of meningioma cells. Experimental data may be provided for targeted therapy for subsequent meningiomas. Methods: from January 1, 2007 to December 31, 2015, paraffin-embedded specimens were collected from 50 patients with meningiomas and 20 normal meningeal specimens from pathology department of the first affiliated Hospital of Nanchang University as control. The meningeal tissue of the control group was removed from the craniocerebral injury patients who received craniocerebral hematoma debridement with bone flap decompression. The expression of TMEM106B,HER-2,VEGF and CD34 proteins in two groups of samples were detected by Max VisionTM immunohistochemical method, and the microvessel density (MVD).) was calculated by UTHSCSA Image Tool graphic and textual analysis software. Results: the positive rate of 1.HER-2 in meningiomas was 36% (18 / 50), but the expression of HER-2 was negative in normal meningeal tissues. (P0.05). However, further study of HER-2 showed that the positive rate of HER-2 did not increase with the malignant degree of meningiomas. The positive rate of HER-2 in WHOI grade meningiomas was 28.6% (6 / 21), and the positive rate of HER-2 in meningiomas of grade WHOI was 28.6% (6 / 21). The positive rate of HER-2 in meningiomas of WHOII grade was 44.4% (8 / 18), WHOIII), which was 36.4% (4 / 11), and there was no significant difference between them (X2 / 2.007, P < 0.01). 2. The positive rate of TMEM106B in meningiomas was 82% (41? 50), but the expression of TMEM106B in normal meningeal tissues was negative. There was significant difference (X2=39.586P0.05) between TMEM106B and TMEM106B. The results of TMEM106B showed that the positive rate of TMEM106B did not increase with the malignant degree of meningiomas. The positive rate of TMEM106B in WHOI grade meningiomas was 81% (17 / 21). The positive rate of TMEM106B in WHOII grade meningiomas was 77.8% (14 / 18), WHOIII grade meningiomas was 90.9% (10 / 11), and there was no significant difference in the expression rate (X 2, 0.004, P < 0.01). (P0.05) .3.MVD and VEGF were negative in normal meningiomas, but increased significantly in meningiomas (18.04 鹵19.85) and 70% (35 渭 50), the difference was statistically significant (X _ 2, 9.692, P 0.05), while the expression rates of MVD and MVD in meningiomas were significantly higher than those in normal meningiomas (18.04 鹵19.85) and 70% (35 鹵50), respectively. CD34 and VEGF were (5.77 鹵10.18) and 66.7% (14 / 21), WHOII,) in different grades of meningiomas: WHOI meningiomas: (5.77 鹵10.18) and 66.7% (P < 0.05). The positive rates of CD34 and VEGF in III grade meningiomas were (26.92 鹵20.53) and 72.41% (21 / 29), the difference was statistically significant (P0.05). Spearman rank correlation analysis showed that HER-2 was positively correlated with VEGF,MVD, her-2 was positively correlated with VEGF (r = 0.113, P0.05), and was positively correlated with MVD (r = 0.058, P0.05). There was a positive correlation between TMEM106B and VEGF (r = 0.293 P0.05), a positive correlation between r=0.146P0.05); VEGF and MVD (P 0.05, r = 0.170) and a positive correlation between HER-2 and TMEM106B (P 0.05, r = 0.115). Conclusion: both 1.HER-2 and TMEM106B are overexpressed in meningioma cells, but there is no significant difference between the positive expression rate and the malignant degree of meningioma. Both HER-2 and TMEM106B are involved in the proliferation and angiogenesis of meningioma cells. 2. Her-2 may influence the proliferation and angiogenesis of meningeal cells by regulating TMEM106B.
【學(xué)位授予單位】：南昌大學(xué)
【學(xué)位級別】：碩士
【學(xué)位授予年份】：2017
【分類號】：R739.45
本文編號：2466909
[Abstract]:Objective: to detect the expression of TMEM106B,HER-2,VEGF and CD34 proteins in meningiomas and to explore the relationship between HER-2 and TMEM106B proteins and the proliferation and angiogenesis of meningioma cells, so as to further understand the pathogenesis and progression of meningiomas, and to explore the relationship between the expression of HER-2 and TMEM106B proteins and the proliferation and angiogenesis of meningioma cells. Experimental data may be provided for targeted therapy for subsequent meningiomas. Methods: from January 1, 2007 to December 31, 2015, paraffin-embedded specimens were collected from 50 patients with meningiomas and 20 normal meningeal specimens from pathology department of the first affiliated Hospital of Nanchang University as control. The meningeal tissue of the control group was removed from the craniocerebral injury patients who received craniocerebral hematoma debridement with bone flap decompression. The expression of TMEM106B,HER-2,VEGF and CD34 proteins in two groups of samples were detected by Max VisionTM immunohistochemical method, and the microvessel density (MVD).) was calculated by UTHSCSA Image Tool graphic and textual analysis software. Results: the positive rate of 1.HER-2 in meningiomas was 36% (18 / 50), but the expression of HER-2 was negative in normal meningeal tissues. (P0.05). However, further study of HER-2 showed that the positive rate of HER-2 did not increase with the malignant degree of meningiomas. The positive rate of HER-2 in WHOI grade meningiomas was 28.6% (6 / 21), and the positive rate of HER-2 in meningiomas of grade WHOI was 28.6% (6 / 21). The positive rate of HER-2 in meningiomas of WHOII grade was 44.4% (8 / 18), WHOIII), which was 36.4% (4 / 11), and there was no significant difference between them (X2 / 2.007, P < 0.01). 2. The positive rate of TMEM106B in meningiomas was 82% (41? 50), but the expression of TMEM106B in normal meningeal tissues was negative. There was significant difference (X2=39.586P0.05) between TMEM106B and TMEM106B. The results of TMEM106B showed that the positive rate of TMEM106B did not increase with the malignant degree of meningiomas. The positive rate of TMEM106B in WHOI grade meningiomas was 81% (17 / 21). The positive rate of TMEM106B in WHOII grade meningiomas was 77.8% (14 / 18), WHOIII grade meningiomas was 90.9% (10 / 11), and there was no significant difference in the expression rate (X 2, 0.004, P < 0.01). (P0.05) .3.MVD and VEGF were negative in normal meningiomas, but increased significantly in meningiomas (18.04 鹵19.85) and 70% (35 渭 50), the difference was statistically significant (X _ 2, 9.692, P 0.05), while the expression rates of MVD and MVD in meningiomas were significantly higher than those in normal meningiomas (18.04 鹵19.85) and 70% (35 鹵50), respectively. CD34 and VEGF were (5.77 鹵10.18) and 66.7% (14 / 21), WHOII,) in different grades of meningiomas: WHOI meningiomas: (5.77 鹵10.18) and 66.7% (P < 0.05). The positive rates of CD34 and VEGF in III grade meningiomas were (26.92 鹵20.53) and 72.41% (21 / 29), the difference was statistically significant (P0.05). Spearman rank correlation analysis showed that HER-2 was positively correlated with VEGF,MVD, her-2 was positively correlated with VEGF (r = 0.113, P0.05), and was positively correlated with MVD (r = 0.058, P0.05). There was a positive correlation between TMEM106B and VEGF (r = 0.293 P0.05), a positive correlation between r=0.146P0.05); VEGF and MVD (P 0.05, r = 0.170) and a positive correlation between HER-2 and TMEM106B (P 0.05, r = 0.115). Conclusion: both 1.HER-2 and TMEM106B are overexpressed in meningioma cells, but there is no significant difference between the positive expression rate and the malignant degree of meningioma. Both HER-2 and TMEM106B are involved in the proliferation and angiogenesis of meningioma cells. 2. Her-2 may influence the proliferation and angiogenesis of meningeal cells by regulating TMEM106B.
【學(xué)位授予單位】：南昌大學(xué)
【學(xué)位級別】：碩士
【學(xué)位授予年份】：2017
【分類號】：R739.45
【參考文獻】
相關(guān)期刊論文 前10條
1 余晶晶;梁偉;周軍;張新華;余波;章如松;周曉軍;;非典型腦膜瘤的臨床病理特點及預(yù)后分析[J];腫瘤學(xué)雜志;2013年07期
2 湯沁;丁倩;林莉;張珍珍;代爭;詹金彪;;針對HER2靶點的抗體藥物研究與腫瘤靶向治療[J];藥學(xué)學(xué)報;2012年10期
3 吳丹;孫國平;彭光輝;馬泰;仲飛;;胃癌組織中HER-2表達(dá)及與血管生成的關(guān)系[J];安徽醫(yī)藥;2012年03期
4 李俊芝;古麗那爾·阿布拉江;張巍;;血管母細(xì)胞瘤50例臨床病理分析[J];新疆醫(yī)科大學(xué)學(xué)報;2010年11期
5 羅勇;林少華;陳信康;;微血管密度與腦膜瘤惡性度的關(guān)系探討[J];臨床醫(yī)藥實踐;2010年12期
6 楊玄勇;王淳良;梅金紅;徐姍;王珊珊;;熒光原位雜交檢測腦膜瘤中HER2基因狀態(tài)[J];中華實驗外科雜志;2009年11期
7 王珊珊;梅金紅;王淳良;徐姍;徐林林;熊一峰;張寶紅;;HER2、Ki-67、TK1蛋白在腦膜瘤中的表達(dá)[J];江西醫(yī)學(xué)院學(xué)報;2009年04期
8 劉莉娜;李曉兵;張博;邵云;張鳳霞;劉甲子;;HER-2原癌基因和腫瘤微血管密度對乳腺癌預(yù)后判斷的一致性研究[J];解放軍醫(yī)學(xué)雜志;2008年07期
9 王淳良;梅金紅;王珊珊;徐林林;秦興義;;腦膜瘤復(fù)發(fā)與微血管密度、血管內(nèi)皮生長因子表達(dá)的關(guān)系[J];中華實驗外科雜志;2008年06期
10 顧應(yīng)江;包長順;梁勇;張苓;劉亮;夏祥國;陳禮剛;;微血管生成與腦膜瘤細(xì)胞增殖活性的關(guān)系[J];瀘州醫(yī)學(xué)院學(xué)報;2007年06期
相關(guān)會議論文 前1條
1 陶英群;李智勇;梁國標(biāo);王運杰;盧亦成;;腦膜瘤手術(shù)切除后復(fù)發(fā)因素的探討[A];中國醫(yī)師協(xié)會神經(jīng)外科醫(yī)師分會第六屆全國代表大會論文匯編[C];2011年
，本文編號：2466909
本文鏈接：http://sikaile.net/yixuelunwen/shenjingyixue/2466909.html
最近更新
教材專著
